Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
NCT02955394Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Sep 2017
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enzalutamide in breast cancer (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Number of Patients With a Preoperative Endocrine Prognostic Index (PEPI) Score Equal to Zero at 16 weeks. Started Sep 2017; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02955394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955394.